影响慢性荨麻疹患者奥玛单抗治疗后复发的因素。停药的方法会影响复发吗?

IF 2.3 4区 医学 Q2 DERMATOLOGY
Petek Üstün, Esra Adışen
{"title":"影响慢性荨麻疹患者奥玛单抗治疗后复发的因素。停药的方法会影响复发吗?","authors":"Petek Üstün, Esra Adışen","doi":"10.5826/dpc.1503a5196","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.</p><p><strong>Objectives: </strong>Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.</p><p><strong>Methods: </strong>Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.</p><p><strong>Results: </strong>A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).</p><p><strong>Conclusions: </strong>Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339098/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?\",\"authors\":\"Petek Üstün, Esra Adışen\",\"doi\":\"10.5826/dpc.1503a5196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.</p><p><strong>Objectives: </strong>Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.</p><p><strong>Methods: </strong>Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.</p><p><strong>Results: </strong>A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).</p><p><strong>Conclusions: </strong>Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"15 3\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339098/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1503a5196\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1503a5196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:Omalizumab被推荐用于慢性荨麻疹(CU),直到自发性缓解,而不是特定的一段时间。治疗后复发率因停药方法而异。目的:本研究旨在探讨奥玛单抗停药方法及其他因素对治疗后复发率的影响。方法:根据停药方式将CU患者分为直接停药、延长治疗间隔至8周、减少治疗剂量至150mg /4周三组。然后比较这些组的复发率。结果:本研究共纳入200例患者。109例直接停用奥玛珠单抗的患者中,65.1%复发。延长治疗间隔至8周的复发率为40.7%,减少剂量至150mg /4周的复发率为15.6%。两种停药方法治疗后复发率差异有统计学意义(P< 0.001)。结论:逐渐减少治疗而不是直接停止治疗可以延长缓解期。将治疗剂量降低至150mg /4周,实现最低复发率,对设计omalizumab停药方案具有重要意义,并为未来的研究提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?

Introduction: Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.

Objectives: Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.

Methods: Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.

Results: A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).

Conclusions: Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
217
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信